Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the expansion of its leadership team with the appointment of Jason S. Baum, Ph.D., as Vice President, Head of Translational Medicine and Christine M. Granfield as Vice President, Head of Regulatory Affairs and Quality.
"It is my pleasure to welcome Jason and Chris to the team," said Douglas E. Onsi, President and Chief Executive Officer of Leap. "Their expertise in the development and approval of novel therapies will prove invaluable as we advance our DKN-01 monoclonal antibody as a treatment for patients with multiple biomarker-defined cancers. We are excited to have them join us to lead and build out these critical functional areas."
Dr. Baum joins Leap with more than a dozen years of industry experience. Most recently, he served as Executive Director and Precision Medicine Leader, General Medicine and Lung Cancer with Novartis Oncology Precision Medicine. Prior to joining Novartis, Dr. Baum held various positions of increasing responsibility with Merrimack Pharmaceuticals, including as Director, Head of Diagnostics and Biomarkers. He started his career as a Product Scientist with Cell Signaling Technology. Dr. Baum holds a Ph.D. in Molecular Biology, Cell Biology and Biochemistry and an M.A. in Biology from Boston University. He holds a B.A. in Biology from Colgate University.
Ms. Granfield joins Leap with more than 25 years of industry experience. Prior to joining Leap, she served as an independent regulatory consultant with Granfield Associates LLC. Previously, she was Senior Director, Regulatory Affairs with Novartis Corporation Oncology Business Unit, where she led the development of regulatory strategy and submissions for companion diagnostics supporting various oncology personalized medicine programs. Prior to her position with Novartis, Ms. Granfield served as Senior Director, Regulatory Affairs with Genzyme Corporation. She also held positions with Boston Scientific Corporation. Ms. Granfield has a BSE, Biomedical Engineering from The Catholic University of America and is a member of the Regulatory Affairs Professional Society.
About Leap Therapeutics
Leap Therapeutics (Nasdaq:LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap has formed a partnership with BeiGene, Ltd. for the rights to develop DKN-01 in Asia (excluding Japan), Australia, and New Zealand. For more information about Leap Therapeutics, visit http://www.leaptx.com
